Results released
Open the filing on sec.gov
ProKidney Corp. (PROK)
Nasdaq: PROK · Biological Products, (No Diagnostic Substances) · Winston-Salem, NC · filing with the SEC since 2021
The companyfiscal 2025, as filed
Revenue$893,000+1075.0%
Net income-$152M+7.2%
Earnings per sharen/a
Operating cash flow-$120M+4.9%
Cash$109M+9.5%
Debtn/a
Shareholders’ equity-$1.01B-1.6%
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202644
Newest filingNov 12 · 8-K
Annual reportMar 18, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$3.0M
Insider buys, 12 months$0.00
Patents granted7
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Revenue $775,000Net income -$182MCash from operations -$153Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Quarterly report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.